Is Traws Pharma, Inc. overvalued or undervalued?
As of November 21, 2025, Traws Pharma, Inc. is rated very attractive due to its undervaluation, highlighted by a low P/E ratio of 0.2145 compared to peers, a strong ROE of 939.05%, and a promising long-term outlook despite recent struggles.
As of 21 November 2025, the valuation grade for Traws Pharma, Inc. moved from attractive to very attractive. The company appears to be undervalued based on its financial metrics. Key ratios include a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. In comparison to its peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which has a P/E of 110.0436, indicating that Traws is significantly cheaper relative to its earnings potential. Additionally, while the industry faces challenges, Traws Pharma's strong ROCE of 496.52% highlights its efficient use of capital. Despite recent struggles, with a YTD return of -73.99% compared to the S&P 500's 12.26%, the long-term outlook remains promising, especially with a 3-year return of 156.67%.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
